Unknown PHASE1 INTERVENTIONAL 6-arm NCT04586803

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers (Single Center, Randomized, Open, 3 Cycles, 6 Sequences)

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Conditions Hyperuricemia Primary Gout

Interventions SHR4640

Updated 5 times since 2020 Last updated: Oct 9, 2020 Started: Oct 31, 2020 Primary completion: Nov 30, 2020 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hyperuricemia and Primary Gout, this trial is ongoing. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 5 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Not Yet Recruiting PHASE1
Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.

Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.